Adaptimmune Therapeutics plc CEO James Noble said Glaxosmithkline plc (GSK) exercised its option "much earlier than they needed to," exclusively licensing rights to research, develop and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program.